Neurocrine Biosciences, Inc.
NBIX
$151.39
-$1.09-0.72%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 27.78% | 16.49% | 11.12% | 21.84% | 24.72% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 27.78% | 16.49% | 11.12% | 21.84% | 24.72% |
| Cost of Revenue | 30.05% | 27.61% | 63.21% | 33.49% | 32.33% |
| Gross Profit | 26.68% | 10.77% | -13.83% | 17.23% | 21.34% |
| SG&A Expenses | 24.46% | 18.31% | 13.74% | 37.87% | 14.74% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 27.05% | 22.52% | 33.88% | 36.12% | 22.29% |
| Operating Income | 29.49% | -1.56% | -77.49% | -12.84% | 30.88% |
| Income Before Tax | 53.34% | 61.76% | -57.39% | -17.96% | 64.62% |
| Income Tax Expenses | 36.03% | 54.76% | 176.40% | 17.82% | 86.15% |
| Earnings from Continuing Operations | 61.40% | 65.38% | -81.80% | -30.20% | 56.20% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 61.40% | 65.38% | -81.80% | -30.20% | 56.20% |
| EBIT | 29.49% | -1.56% | -77.49% | -12.84% | 30.88% |
| EBITDA | 29.12% | -1.48% | -71.93% | -11.47% | 30.40% |
| EPS Basic | 64.16% | 68.41% | -81.79% | -31.31% | 51.26% |
| Normalized Basic EPS | 27.74% | -0.87% | -64.38% | -10.73% | 29.49% |
| EPS Diluted | 64.52% | 68.25% | -81.14% | -30.74% | 51.22% |
| Normalized Diluted EPS | 27.81% | 0.17% | -64.04% | -9.81% | 29.62% |
| Average Basic Shares Outstanding | -1.68% | -1.79% | -0.10% | 1.63% | 3.27% |
| Average Diluted Shares Outstanding | -1.73% | -2.79% | -1.06% | 0.59% | 3.17% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |